The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer

Summary Background Evaluation of the prognostic significance of a group of tumour markers and their ability to predict response to chemotherapy may allow better targeting of palliative treatment in advanced colorectal cancer. Patients and methods Using a prospectively acquired database of 377 patients (pts) with advanced colorectal adenocarcinoma, the prognostic significance of serum CEA (342 pts), 0HCG (203 pts), AFP (208 pts), CA125 (150 pts), CA19-9 (76 pts) as well as C-erb B-2 (197 pts), pHCG (197 pts) immunohistochemistry was investigated. Serum markers were taken prior to 5-FU based chemotherapy and immunohistochemistry was performed on diagnostic samples. Results Tumour markers of poor prognostic significance in the univariate analysis were CEA > 5 [ig/1 (p ─ 0.006; median survival (MS) 59 weeks vs. 38 weeks) and CA125 > 35 U/ml (p ─ 0.01; MS 51 weeks vs. 30 weeks). Tumour markers elevated at greater than 10 times the normal value which correlated with a poor prognosis were CEA (p─0.001; MS 47 weeks vs. 35 weeks), Serum 0HCG (p 2) and poorly differentiated tumour histology were also correlated to poor survival. In the multivariate analysis, tumour markers of independent poor prognosis were CEA > 5 [ig/1 (Hazard Ratio (HR) 1.8; 95% Confidence Internal (CI) 2.8−1.2), CEA > 50 ng/1 (HR 1.6; CI 2.1−1.2), CA125 > 35 U/ml (HR 1.5; CI 2.3−1.0), CA125 > 350 U/ml (HR 5.0; CI 9.6−2.6) and serum PHCG > 40 IU/1 (HR 11.7; CI 30−4.5). Poor performance status (HR 6.7−5.0) and poorly differentiated histology (HR 2.8-1.0) were the other important factors in the model. No pretreatment tumour marker correlated with response to chemotherapy. Conclusions This is the largest prognostic study of each tumour marker in advanced disease and it clarifies previous conflicting reports. Serum AFT, CA19-9 and immunohisto-chemical stains PHCG and C-erb B-2 have no prognostic significance. Serum CEA, PHCG, CA125 in advanced colorectal cancer prior to chemotherapy do convey an independent poor prognosis which may reflect not just tumour burden but aggressive biology.

[1]  T R Fleming,et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. , 1993, JAMA.

[2]  S. Shousha,et al.  HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. , 1992, Journal of Clinical Pathology.

[3]  E. Campo,et al.  Prognostic value of CA 19.9 levels in colorectal cancer. , 1992, Annals of surgery.

[4]  S. Pyrhönen,et al.  Elevated CA19‐9 as the most significant prognostic factor in advanced colorectal carcinoma , 1992, Journal of surgical oncology.

[5]  T. Wobbes,et al.  Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. , 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[6]  H. Wieand,et al.  A phase ii study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer , 1990, Cancer.

[7]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.

[8]  J. Jessup,et al.  Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. , 1990, Journal of the National Cancer Institute.

[9]  W. Gullick,et al.  c‐erbB‐2 oncoprotein expression in primary human tumors , 1990, Cancer.

[10]  Y. Shiloh,et al.  Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance , 1989, International journal of cancer.

[11]  T. Kosaka,et al.  Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. , 1989, British Journal of Cancer.

[12]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[13]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[14]  Abraham Fuks,et al.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule , 1989, Cell.

[15]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[16]  S. Steinberg,et al.  Determinants of survival in patients with unresectable colorectal liver metastases , 1989, Journal of surgical oncology.

[17]  N. Kemeny,et al.  Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement , 1989, Cancer.

[18]  H. Deguchi,et al.  Carcinoembryonic antigen and carbohydrate antigen 19‐9 levels of peripheral and draining venous blood in colorectal cancer patients correlation with histopathologic and immunohistochemical variables , 1988, Cancer.

[19]  Y. Shiloh,et al.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. , 1988, Cancer research.

[20]  I. Fidler,et al.  Growth potential of human colorectal carcinomas in nude mice: association with the preoperative serum concentration of carcinoembryonic antigen in patients. , 1988, Cancer research.

[21]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[22]  E. Campo,et al.  Human chorionic gonadotropin in colorectal carcinoma an immunohistochemical study , 1987, Cancer.

[23]  H. Egami,et al.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. , 1987, Gut.

[24]  H. Egami,et al.  Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive System , 1986, The American journal of the medical sciences.

[25]  R. Tubbs,et al.  Measurement of a monoclonal‐antibody‐defined antigen (CA 19‐9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigen , 1985, Cancer.

[26]  P. Wilkinson,et al.  Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. , 1984, British Journal of Cancer.

[27]  N. Wolmark,et al.  The Prognostic Significance of Preoperative Carcinoembryonic Antigen Levels in Colorectal Cancer: Results from NSABP Clinical Trials , 1984 .

[28]  O. Mäkelä,et al.  Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. , 1984, British Journal of Cancer.

[29]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[30]  M. O'brien,et al.  Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. , 1981, The American journal of medicine.

[31]  H. Fox,et al.  An immunohistochemical study of the significance of HCG secretion by large bowel adenocarcinomata. , 1979, Journal of clinical pathology.

[32]  M. O’connell,et al.  Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. , 1978, Annals of internal medicine.

[33]  Ding‐Shinn Chen,et al.  Serum alphafetoprotein in hepatocellular carcinoma , 1977, Cancer.

[34]  M. Ostrander,et al.  Human chorionic gonadotrophins (hCG) in nontrophoblastic neoplasms. Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasms , 1976, Cancer.

[35]  T. Waldmann,et al.  α-Fetoprotein in Nonneoplastic Hepatic Disorders , 1975 .

[36]  T. Waldmann,et al.  Serum α-Fetoprotein in Patients with Neoplasms of the Gastrointestinal Tract , 1975 .

[37]  T. Waldmann,et al.  The use of a radioimmunoassay for alpha‐fetoprotein in the diagnosis of malignancy , 1974, Cancer.

[38]  G. Braunstein,et al.  Ectopic production of human chorionic gonadotrophin by neoplasms. , 1973, Annals of internal medicine.